Literature DB >> 7943542

Fatal neurotoxicity of arteether and artemether.

T G Brewer1, S J Grate, J O Peggins, P J Weina, J M Petras, B S Levine, M H Heiffer, B G Schuster.   

Abstract

Artemisinin (qinghaosu) and several derivatives have been developed and are in use as antimalarial drugs but scant information is available regarding animal or human toxicity. Following a eight-day, multiple-dose, pharmacokinetic study of arteether (AE) (10 mg/kg/day [n = 6] and 20 mg/kg/day [n = 6]) in dogs, all high-dose animals displayed a progressive syndrome of clinical neurologic defects with progressive cardiorespiratory collapse and death in five of six animals. Neurologic findings included gait disturbances, loss of spinal and pain response reflexes, and prominent loss of brain stem and eye reflexes. Animals had prolongation of QT interval corrected for rate (QTc) on electrocardiograms (ECGs) with bizarre ST-T segment changes. Prominent neuropathic lesions were noted to be primarily limited to the pons and medulla. Similar lesions with dose-related severity were noted in eight other dogs studied in a second study with intramuscular (IM) administration of AE in sesame oil during a 28-day, dose-ranging study using 5, 10, 15, and 20 mg/kg/day. Injury, graded by a pathologist blinded to the dose group, showed a dose-related, region-specific injury in all animals that was most pronounced in the pons. Further studies in Sprague-Dawley rats using IM administration of AE and artemether (AM) at a dose of 12.5-50 mg/kg/day for 28 days confirmed the onset of a clinical neurologic syndrome with dose-related changes in body weight, activity, and seizure-like activity, stereotypic movement disorders, and ECG changes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7943542     DOI: 10.4269/ajtmh.1994.51.251

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  46 in total

1.  Establishment of an in vitro screening model for neurodegeneration induced by antimalarial drugs of the artemisinin-type..

Authors:  G Schmuck; R K Haynes
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  Safety assessment of peroxide antimalarials: clinical and chemical perspectives.

Authors:  B K Park; P M O'Neill; J L Maggs; M Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

Review 3.  The role of plant-derived drugs and herbal medicines in healthcare.

Authors:  P A De Smet
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

4.  Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro.

Authors:  S J Kim; M S Kim; J W Lee; C H Lee; H Yoo; S H Shin; M J Park; S H Lee
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-05       Impact factor: 4.553

Review 5.  Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.

Authors:  N J White; M van Vugt; F Ezzet
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

Review 6.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

7.  Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children.

Authors:  Catherine O Falade; Oluwatoyin O Ogunkunle; Hannah O Dada-Adegbola; Adegoke G Falade; Patricia Ibarra de Palacios; Philip Hunt; Mailis Virtanen; Ayoade M Oduola; Lateef A Salako
Journal:  Malar J       Date:  2008-11-27       Impact factor: 2.979

8.  The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria.

Authors:  Michael T Ambler; Lilly M Dubowitz; Ratree Arunjerdja; Eh Paw Hla; Kyaw Lay Thwai; Jacher Viladpainguen; Pratap Singhasivanon; Christine Luxemburger; François Nosten; Rose McGready
Journal:  Malar J       Date:  2009-09-02       Impact factor: 2.979

9.  Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria.

Authors:  Stephan Ehrhardt; Christian G Meyer
Journal:  Ther Clin Risk Manag       Date:  2009-10-12       Impact factor: 2.423

10.  Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria?

Authors:  Richard J Maude; Katherine Plewes; M Abul Faiz; Josh Hanson; Prakaykaew Charunwatthana; Sue J Lee; Joel Tärning; Emran Bin Yunus; M Gofranul Hoque; Mahatab Uddin Hasan; Amir Hossain; Niklas Lindegardh; Nicholas P J Day; Nicholas J White; Arjen M Dondorp
Journal:  Am J Trop Med Hyg       Date:  2009-01       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.